How did the CSL (ASX:CSL) share price respond last earnings season?

How did the company's shares react following its H1 FY21 result?

| More on:
A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has climbed 8% over the past month, reflecting renewed investor optimism of late. It's no secret that the company is due to report its much-anticipated FY21 full-year results on Wednesday.

After Monday's market close, the global biotech's shares finished the day flat at $297.49. In early trade on Tuesday, their price has dropped 0.29% to $296.64.

Let's take a peek to see how CSL performed for the first half of FY21 and how its share price reacted.

What did CSL report for H1 FY21?

During mid-February, CSL delivered its first-half result, citing a strong growth despite COVID-19 challenges.

Here's a summary of the financial numbers that CSL posted for its last earnings season.

  • Total revenue up 16.9% to US$5,739 million driven by 9% increase in CSL Behring revenue and a 38% jump in Seqirus revenue
  • Earnings before interest and tax (EBIT) up 44.4% to US$2,358 million
  • Net Profit After Tax (NPAT) up 46.2% to US$1,810 million

Following the release, CSL shares rocketed from $279.51 on 17 February to an intraday high of $295.30 on 18 February. This represents a jump of around 5.6% for the blue-chip company.

However, investors were quick to take profit off the table as CSL flagged plasma collection issues in its report. In the weeks after, the company's shares were trading at a 52-week low of $242.00 apiece.

What should investors look out for this earnings season?

According to Goldman Sachs, CSL is expected to negatively surprise the market tomorrow on its FY21 result. The broker notes that the result is set to be challenging but, in itself, a minor focus amid the COVID-19 chaos.

CSL reaffirmed its earnings to be within 3% to 8% ahead for the FY21 full-year, despite delivering a 25% increase at H1 FY21. This points to an earnings decline of 47% to 58% in the second half.

Cost pressures are also likely to persist into FY22 as CSL aims to recover the collection of plasma to pre-pandemic levels.

In addition, the development of mRNA-based flu vaccines could be a concern for the company's Seqirus business. The threat of competitive entry into this market will be carefully watched. 

CSL share price snapshot

Year-to-date, the CSL share price has continued to move sideways, reflecting a 5% gain for the period. When looking at a longer time frame, the company's shares are up 6% over the last 12 months.

CSL commands a market capitalisation of roughly $135.4 billion, making it the third largest company on the ASX.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two doctors smile as they sit together at a desk looking at a patient's x-ray.
Healthcare Shares

Why Macquarie rates this ASX All Ords medical imaging stock a buy

The broker maintains its outperform rating on the stock.

Read more »

A man in a hospital bed on a drip gives a thumbs up sign.
Healthcare Shares

Macquarie predicts 86% upside for this ASX 200 healthcare stock

Shares could almost double over the next 12 months, according to the broker.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »